Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02293018 · ClinicalTrials.gov registry record · Phase 1

Pharmacokinetic Study of MTC896 Gel in Subjects With Acne

A Phase 1 study, sponsored by Mimetica Pty Limited.

Completed
Registry status
Phase 1
Development phase
32
Enrollment target

NCT02293018 is a Phase 1 study that has completed, run by Mimetica Pty Limited. The registered enrollment target is 32 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02293018, a Phase 1 study, has completed, sponsored by Mimetica Pty Limited.

COMPLETED
Registry status
Phase 1
Development phase
32 participants
Enrollment target

Study Summary

The purpose of this study is to determine the pharmacokinetic properties of topically applied MTC896 Gel following application of 0.75% (w/w) MTC896 Gel once daily and twice daily and 1.5% (w/w) once daily over 4 weeks in the treatment of acne.

Interventions

  • DRUG 0.75% (w/w) MTC896 Gel Once Daily
  • DRUG 0.75% (w/w) MTC896 Gel Twice Daily
  • DRUG 1.5% (w/w) MTC896 Gel Once Daily

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2014-08
Est. Completion 2015-01
Phase Phase 1

Sponsor

Mimetica Pty Limited

2 total trials

What the Registry Record Tells You About NCT02293018

The ClinicalTrials.gov registry entry for NCT02293018 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mimetica Pty Limited, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which 0.75% (w/w) MTC896 Gel Once Daily is the first listed.

NCT02293018 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02293018 about?

NCT02293018 is a clinical study titled "Pharmacokinetic Study of MTC896 Gel in Subjects With Acne". The purpose of this study is to determine the pharmacokinetic properties of topically applied MTC896 Gel following application of 0.75% (w/w) MTC896 Gel once daily and twice daily and 1.5% (w/w) once daily over 4 weeks in the treatment of acne.

What is the current status of trial NCT02293018?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2014-08. Estimated completion is 2015-01.

What interventions are being tested in trial NCT02293018?

The interventions under investigation include: 0.75% (w/w) MTC896 Gel Once Daily (DRUG), 0.75% (w/w) MTC896 Gel Twice Daily (DRUG), 1.5% (w/w) MTC896 Gel Once Daily (DRUG).

Who is sponsoring clinical trial NCT02293018?

This trial is sponsored by Mimetica Pty Limited, which has 2 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.